{
  "scores": {
    "rubric_version": "v3.0-2025-10-14",
    "items": {
      "Title": {
        "score": 0,
        "evidence": "Purpose: This aim of this study was to investigate the analgesic efficacy and safety of lesser occipital nerve combined with great auricular nerve block (LOGAB) for craniotomy via a suboccipital retrosigmoid approach."
      },
      "Trial_Design": {
        "score": 1,
        "evidence": "Patients underwent vestibular schwannoma resection via a suboccipital retrosigmoid approach were randomly assigned to receive ultrasound-guided unilateral LOGAB with 5 ml of 0.5% ropivacaine (LOGAB group) or normal saline (NSB group)."
      },
      "Participants": {
        "score": 1,
        "evidence": "Patients underwent vestibular schwannoma resection via a suboccipital retrosigmoid approach were randomly assigned to receive ultrasound-guided unilateral LOGAB with 5 ml of 0.5% ropivacaine (LOGAB group) or normal saline (NSB group)."
      },
      "Intervention": {
        "score": 2,
        "evidence": "Patients underwent vestibular schwannoma resection via a suboccipital retrosigmoid approach were randomly assigned to receive ultrasound-guided unilateral LOGAB with 5 ml of 0.5% ropivacaine (LOGAB group) or normal saline (NSB group)."
      },
      "Objective": {
        "score": 1,
        "evidence": "Purpose: This aim of this study was to investigate the analgesic efficacy and safety of lesser occipital nerve combined with great auricular nerve block (LOGAB) for craniotomy via a suboccipital retrosigmoid approach."
      },
      "Method_Outcome": {
        "score": 2,
        "evidence": "Numeric rating scale (NRS) scores at rest and motion were recorded within 48 h after surgery."
      },
      "Randomisation_Allocation": {
        "score": 1,
        "evidence": "Patients underwent vestibular schwannoma resection via a suboccipital retrosigmoid approach were randomly assigned to receive ultrasound-guided unilateral LOGAB with 5 ml of 0.5% ropivacaine (LOGAB group) or normal saline (NSB group)."
      },
      "Blinding": {
        "score": 0,
        "evidence": "Not reported"
      },
      "Number_Randomised": {
        "score": 1,
        "evidence": "Among 59 patients who were randomized, 30 patients received ropivacaine, and 29 patients received saline."
      },
      "Number_Analysed": {
        "score": 1,
        "evidence": "Among 59 patients who were randomized, 30 patients received ropivacaine, and 29 patients received saline."
      },
      "Result_Outcome": {
        "score": 2,
        "evidence": "NRS scores at rest (1.8 \u00b1 0.5 vs. 3.2 \u00b1 0.8, P = 0.002) and at motion (2.2 \u00b1 0.7 vs. 3.2 \u00b1 0.6, P = 0.013) of LOGAB group were lower than those of NSB group within 48 h after surgery."
      },
      "Harms": {
        "score": 1,
        "evidence": "No patients reported any adverse events."
      },
      "Trial_Registration": {
        "score": 1,
        "evidence": "Clinical trial registration number: Chictr.org.cn ChiCTR2000038798."
      },
      "Funding": {
        "score": 0,
        "evidence": "Not reported"
      }
    },
    "total_score": 14,
    "max_score": 25
  },
  "model": "gpt-4o"
}